Related Experiment Videos
[Recombinant human erythropoietin in premature infants. Evaluation of a one year experience]
A S Trentesaux1, L Egreteau, B Santerne
1Service de réanimation polyvalente infantile, American Memorial Hospital (URIP), Reims, France.
Insights
Early recombinant human erythropoietin (rhEPO) treatment did not significantly reduce overall red blood cell transfusions in premature infants. However, it did decrease transfusions between days 16-45, particularly for infants weighing 1000-1250g.
Area of Science:
- Neonatal Medicine
- Hematology
- Pediatric Critical Care
Background:
- Premature infants often require red blood cell transfusions due to anemia.
- Recombinant human erythropoietin (rhEPO) has been proposed to reduce transfusion needs.
Purpose of the Study:
- To investigate the efficacy of early rhEPO treatment in reducing red blood cell transfusions in premature infants.
Main Methods:
- A cohort of 50 premature infants (gestational age <= 32 weeks) received rhEPO (750 UI/kg/week) for six weeks.
- Compared with 50 untreated control infants admitted the previous year.
Main Results:
- No significant difference in the overall number of transfused infants or transfusions per infant until discharge.
- Treated infants received fewer transfusions per infant between day 16 and day 45.
- Infants with birth weight between 1,000-1,250 g showed reduced transfusions in the rhEPO group.
Conclusions:
- Early rhEPO treatment may be beneficial but requires combination with conservative transfusion strategies.
- Minimizing phlebotomy losses and early iron supplementation are crucial alongside rhEPO therapy.
- rhEPO shows potential in specific subgroups and when integrated into a comprehensive transfusion management plan.
Unlabelled:
Recently, recombinant human erythropoietin (rhEPO) has been claimed to diminish red blood cell transfusions in premature infants. After a year of experience, we investigated whether early rhEPO treatment would reduce the need for transfusion.
Patients And Methods:
Fifty premature infants of gestational age < or = 32 weeks admitted to our NICU in 1997, received rhEPO 750 UI/kg/week from day 3 to 5 for six weeks. They were compared with 50 untreated controls admitted in 1996.
Results:
The treatment and control groups did not differ for gestational age, weight at birth, CRIB score, and blood losses. We were not able to detect any difference in the number of transfused infants, and in the number of transfusions per infant until discharge. However, treated infants received significantly fewer transfusions per infant between day 16 and day 45 (0.42 +/- 0.67 vs. 0.8 +/- 0.99). Infants with a birth weight between 1,000-1,250 g received fewer transfusions in the EPO group.
Conclusion:
rhEPO treatment can be useful, but in association with other procedures: conservative transfusion criteria, minimization of phlebotomy losses and early iron supplementation.